Abstract:Acute kidney injury leading to chronic kidney disease through tubulointerstitial fibrosis is a major challenge in nephropathy. Several signaling pathways promote interstitial fibrosis; however, effective suppression of fibrosis may require blockade of more than one pathway. This study investigated whether blockade of Smad3 and c-Jun N-terminal kinase (JNK) signaling gives added suppression of interstitial fibrosis in folic acid nephropathy. A single high dose of folic acid (FA) causes acute tubular damage in C57BL/6J mice followed by interstitial fibrosis and chronic renal impairment. Co-activations of Smad3 and JNK signaling occur in both tubular epithelial cells and myofibroblasts in areas of tubulointerstitial damage and fibrosis in both murine FA-induced nephropathy and human IgA nephropathy. Groups of mice were treated with a Smad3 inhibitor (SIS3), a JNK inhibitor (SP600125), or a combination from day 6 after FA administration until being killed on day 28. Each drug efficiently inhibited its specific target (Smad3 phosphorylation or c-Jun phosphorylation) without affecting the other pathway. Given alone, each drug partially reduced renal fibrosis, whereas the combination therapy gave an additive and profound protection from renal fibrosis and improved renal function. Inhibition of Smad3 and/or JNK signaling activities prevented down-regulation of PGC-1α in tubular epithelial cells and up-regulation of PGC-1α in myofibroblasts during FA-induced renal fibrosis and inflammation. The expression of PGC-1α was upregulated in Smad3 -/- NRK52E cells while downregulated in Smad3 -/- NRK49F cells, suggesting that Smad3 signaling may regulate expression of PGC-1α in renal tubular epithelial cells and fibroblasts in distinct fashion. In vivo and cell culture studies also indicate that Smad3 and JNK signaling cooperate to cause mitochondrial dysfunction and cell damage in tubular epithelial cells via direct actions on the transcription of PGC-1α. These pathways also act cooperatively to promote renal fibroblast proliferation in tempo-spatial fashion. In conclusion, we have identified a potential combination therapy for progressive renal fibrosis which operates, in part, through modifying mitochondrial function.

Pharmacologic Inhibiting STAT3 Delays the Progression of Kidney Fibrosis in Hyperuricemia-Induced Chronic Kidney Disease.

A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy.

Inhibition of STAT3 in tubular epithelial cells prevents kidney fibrosis and nephropathy in STZ-induced diabetic mice

Pharmacological Inhibition of STAT6 Ameliorates Myeloid Fibroblast Activation and Alternative Macrophage Polarization in Renal Fibrosis

Inhibition of STAT3 Acetylation is Associated with Attenuated Renal Fibrosis in the Obstructed Kidney

STX‐0119, a novel STAT3 dimerization inhibitor, prevents fibrotic gene expression in a mouse model of kidney fibrosis by regulating Cxcr4 and Ccr1 expression

Heat Shock Protein 72 Antagonizes STAT3 Signaling to Inhibit Fibroblast Accumulation in Renal Fibrogenesis.

Natural Flavonoid Pectolinarigenin Alleviated Kidney Fibrosis Via Inhibiting the Activation of TGFβ/SMAD3 and JAK2/STAT3 Signaling.

Blocking Interleukin-6 Trans-Signaling Protects Against Renal Fibrosis by Suppressing STAT3 Activation

Blockade of STAT3 signaling alleviates the progression of acute kidney injury to chronic kidney disease through antiapoptosis

Blockade Of Enhancer Of Zeste Homolog 2 Alleviates Renal Injury Associated With Hyperuricemia

Combined Blockade of Smad3 and JNK Pathways Ameliorates Progressive Fibrosis in Folic Acid Nephropathy

Role of Stat3 Signaling in Control of EMT of Tubular Epithelial Cells During Renal Fibrosis.

STAT3 Protein–Protein Interaction Analysis Finds P300 as a Regulator of STAT3 and Histone 3 Lysine 27 Acetylation in Pericytes

Pharmacological inhibition of Src family kinases attenuates hyperuricemic nephropathy

EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy.

Pharmacological Inhibition of Fatty Acid-Binding Protein 4 Alleviated Kidney Inflammation and Fibrosis in Hyperuricemic Nephropathy

STAT3 inhibition attenuates the progressive phenotypes of Alport syndrome mouse model

Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats

Inhibition of Jak/STAT signaling ameliorates mice experimental nephrotic syndrome.

Delayed treatment with an autophagy inhibitor 3-MA alleviates the progression of hyperuricemic nephropathy